76 NATURALS
20 18 16 14 12 10 8 6 4 2 0
Control +32% +22% +25%
25 20 15 10 5 0
0.5% 1% 2.5%
Figure 8: Evaluation of the anti-microbial effect of the skincare active on human keratinocytes, study of the antimicrobial peptide HBD-2
to stimulate the production of these important peptides. The skincare active was found to enhance the expression of antimicrobial peptides LL-37, beta-defensin 2, and psoriasin. These peptides are crucial for the skin’s innate immune response and contribute to its ability to combat harmful microorganisms. At concentrations of 0.5%, 1% and 2.5%,
the skincare active increased the expression of Beta-defensine2 (HBD-2) by 22%, 26% and 32% respectively. At concentrations of 0.5%, 1% and 2.5%, the skincare active increased the expression of peptide LL-37 by 19%, 24% and 31% respectively. At concentrations of 0.5%, 1% and 2.5%,
the skincare active increases the expression of psoriasin 19%, 28% and 36%. These findings highlight the protective
effect of the skincare active, as it enhances the expression of antimicrobial peptides that strengthen the skin’s defence mechanisms against potential pathogens. This information is valuable for understanding how the skincare active supports overall skin health and maintains a balanced microbial environment.
Soothing and immuno-modulating effect The anti-inflammatory potential of the skincare active has been evaluated on reconstituted
200 180 160 140 120 100 80 60 40 20 0
Negative control
+68% -20% -26% -30% Control +31% +19% +24%
3.5 3
+19%
2.5 2
1.5 1
0.5 0
0.5% 1% 2.5%
Figure 9: Evaluation of the anti-microbial effect of the skincare active on human keratinocytes, study of the antimicrobial peptide LL-37
epidermis using the CellSystems model. Keratinocytes, which play a crucial role in the immune response, not only produce antimicrobial peptides but also pro- inflammatory cytokines such as IL1 (alpha and beta), IL8, IL6, and TNF-alpha. When using the skincare active at 0.5%, the
results showed a decrease in TNF-alpha levels of 17% and IL1-alpha levels of 20%. When using the skincare active at 1%, the results showed a significant decrease in TNF-alpha levels of 21% and IL1-alpha levels of 26%. When using the skincare active at 1.5%, the
results showed a significant decrease in TNF- alpha levels of 24% and IL1-alpha levels of 30%. These pro-inflammatory cytokines are
associated with skin inflammation, and their reduction indicates the potential of the skincare active to calm and soothe irritated skin, making it suitable for sensitive skin types.
Conclusion This skincare active from Naolys represents a significant breakthrough in skincare, harnessing the power of the skin microbiome to enhance radiance and soothe the skin. Its multi-faceted action on the skin’s defence mechanisms reinforces the cutaneous barrier, promotes cellular renewal, rebalances the microbial environment, and enhances the expression of
200 180 160 140 120 100 80 60 40 20 0
Passive control (UVB)
(0.5%) + UVB
+ UVB (1%)
(2.5%) + UVB
Figure 11: Evaluation of the anti-microbial effect of the skincare active on human keratinocytes, study of the antimicrobial peptide Psoriasin
PERSONAL CARE October 2023
Negative control
Control 0.5% 1% 2.5%
Figure 10: Evaluation of the anti-microbial effect of the skincare active on human keratinocytes, study of the antimicrobial peptide Psoriasin
antimicrobial peptides. These scientifically validated effects are
supported by in vitro and clinical studies, providing a solid foundation for the efficacy and benefits of Serene Skin Sage. By combining the wisdom of nature with
advanced biotechnology, Naolys continues to drive innovation in the skincare industry, offering consumers an attractive and effective solution for their skincare needs. Experience the transformative power of nature and cutting- edge biotechnology with Serene Skin Sage – a skincare active that represents a harmonious fusion of science and botanical wonders.
References 1. Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, Zupancic A. (2001). Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. Journal of Ethnopharmacology. 75(2-3), 125-132
2. Misra BB, Dey S, Prajapati V, Singh S, Yadav N, Gupta, AK. Phytochemical and pharmacological potential of Salvia officinalis L. Journal of Pharmacy and Pharmacology. 2016; 68(2), 137-161
3. Barnes J, Anderson LA. Herbal medicines: A guide for healthcare professionals. 2012. Pharmaceutical Press
+55% -17% -21% -24%
+36% +28%
PC
Passive control (UVB)
(0.5%) + UVB
+ UVB
(1%)
(2.5%) + UVB
Figure 12: Study of the anti-inflammatory potential on reconstituted epidermis using the CellSystems model, expression of the pro-inflammatory cytokine TNF-alpha
www.personalcaremagazine.com
IL1-a (pg/ml)
HBD-2(ng/ml)
LL-37 (ng/ml)
IL1-a (pg/ml)
Psoriasin (ng/ml)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108
